Companies featured in this edition of the newsletter: ACTC, CHIP, CVM, DKAM, ENZ, IWEB, MBCI, MFGD, PHC

Markets rebounded last week, on the strength of upbeat productivity and manufacturing reports that led to solid gains in all of the major indices. Despite news that the unemployment rate had hit its highest levels in 25 years, the Dow managed to end the week up 310 points, gaining 3.2% on the week to close at 10,023, up 14.2% on the year. The Nasdaq posted a gain of 3.3%, closing at 2112 and extending its yearly gains to 34%, while the S&P 500 and Russell 2000 advanced 3.2% and 3.1% respectively on the week to bring their YTD performance to 18.4% and 16.2%.

Several better than expected economic reports provided buying incentive throughout much of the week, as investors managed to shake off the previous week’s negative bias to send indices into positive territory

...

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

 

Friday August 28, 2009

PennyOmega.com Stock Report!

**************************************************************

The Farmers National Bank of Emlenton, the subsidiary operating bank of Emclaire Financial Corp. (OTCBB: EMCF), announced today that the Bank completed its acquisition of the full-service branch office of National City Bank (”National City”), now a part of The PNC Financial Services Group, Inc. (NYSE: PNC), located in Titusville, Pennsylvania. The office will open for full service as a Farmers National Bank office on Monday, August 31, 2009.

Seamless Corporation (OTCBB: SMWF) announced today that it and one of America’s favorite product promoters, Dr. Gadget, further solidified their relationship by Seamless’ acquisition of www.gadgetenterprises.com, an eCommerce website. Terms

...

Seattle-based biotechnology company Dendreon (DNDN) recently raised more than $200 million through the issuance of 10.7 million shares of its common stock in a public offering. In addition, it granted offering manager Deutsche Bank Securities an over-allotment of 1.3 million shares to support the manufacture and marketing of Provenge.

Provenge, a therapeutic vaccine candidate being developed by Dendreon for the treatment of prostate cancer is likely to receive FDA approval in the first half of 2010. Unlike traditional vaccines that prevent diseases, Provenge treats it by stimulating the body's own immune system to attack cancer cells.

We remind investors that the company met with disappointment in 2007 when the FDA asked for further data before approving it. The disappointing news had caused the company to retrench 15% of its workforce and sent its shares on a downward journey.

However, in April 2009, Dendreon reported positive results from its IMPACT (IMmunotherapy for Prostrate

...

The second quarter of 2009 was filled with gains and plenty of plain. After looking at the quarter’s winners and losers, one thing is obvious, biotechs can make or break your portfolio.

Sometimes the best way to see where you are going is to look where you have been. Of course every financial commentator always covers his backside by telling you “past performance is not an indication of future returns,” just as he whips out charts of historic action.

With the second quarter in the history books, we can learn who were the winners and the losers and work to uncover any important patterns or indicators. The results may be surprising.

I will start with the top three gainers, all listed on the Nasdaq exchange.

Dendreon (NASDAQ:DNDN) wins top honors with a quarterly gain of 495%. The biotech company that was trading for just $2.55 per share in March is now

...

For Immediate Release

Chicago, IL - June 1, 2009 - Zacks.com releases the latest Industry Outlook. Today's interview is with senior analyst Grant Zeng, who talks about the Biotech Industry, including Myriad Genetics (MYGN), Onyx Pharmaceuticals Inc. (ONXX), AMAG Pharmaceuticals Inc. (AMAG), Dendreon (DNDN) and 3SBio Inc. (SSRX).

A synopsis of today's Industry Outlook is presented below. The full article can be read at http://at.zacks.com/?id=2678.

Our best picks at this point include Myriad Genetics (MYGN), Onyx Pharmaceuticals Inc. (ONXX) and AMAG Pharmaceuticals Inc. (AMAG), Dendreon (DNDN) and 3SBio Inc. (SSRX). We have different reasons for a BUY rating for each of the four companies, but all of these companies have one thing in common -- strong balance sheets, which eliminates immediate financing needs.

Both MYGN

...

* E*Trade (NASDAQ:ETFC) said the company faces regulatory pressure to increase its capital following release of its seventh straight quarterly loss. First quarter results indicated a 41 cent loss per share, one cent more than expected, as revenues fell 6% year-over-year to $497.3 million

* Verizon (NYSE:VZ) shares gained Tuesday amid rumors the company is in talks with Apple (NASDAQ:AAPL) about a possible new iPhone and/or Microsoft (NASDAQ:MSFT) on an iPhone competitor

* Dendreon's (NASDAQ:DNDN) drug Provenge was found to increase lives of advanced prostate cancer victims by 4.1 months, increasing the likelihood of FDA approval

* US Steel (NYSE:X) reported a worse-than-expected first quarter loss of $3.84 per share versus expected loss of $1.69 per share. The company slashed its dividend to 5 cents from 30 cents; expects another operating loss in the second quarter; plans 18 million common share offering and $300 million senior notes due 2014; will curb capital spending

...

Just wait until the opening bell starts ringing Wednesday, Dendreon (NASDAQ:DNDN) will be counting their money like Nino Brown from a high-rise penthouse on Cloud 9.  Provenge is a winner and appears to be on its way to become the first approved therapeutic vaccine for any type of cancer. Dendreon shares were halted after they plunged 45% in a two-minute span to $11.81 on Nasdaq in the hour leading up to release of the study results. When trading resumed after hours, the shares rose 130% to a new record high of ...